Humira and Idiopathic pulmonary fibrosis - a phase IV clinical study of FDA data

Summary:

Idiopathic pulmonary fibrosis is found among people who take Humira, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Humira and have Idiopathic pulmonary fibrosis. It is created by eHealthMe based on reports of 647,817 people who have side effects when taking Humira from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jun, 09, 2023

647,817 people reported to have side effects when taking Humira.
Among them, 1,994 people (0.31%) have Idiopathic pulmonary fibrosis.

What is Humira?

Humira has active ingredients of adalimumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 650,663 Humira users for its effectiveness, alternative drugs and more.

What is Idiopathic pulmonary fibrosis?

Idiopathic pulmonary fibrosis (chronic lung disease) is found to be associated with 2,462 drugs and 2,146 conditions by eHealthMe.

Number of Humira and Idiopathic pulmonary fibrosis reports submitted per year:

Could Humira cause Idiopathic pulmonary fibrosis?

* Approximation only. Some reports may have incomplete information.

Do you take Humira and have Idiopathic pulmonary fibrosis?

Check whether Idiopathic pulmonary fibrosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .

Related studies

How severe was Idiopathic pulmonary fibrosis and when was it recovered:

Idiopathic pulmonary fibrosis in Humira

Expand to all the drugs that have ingredients of adalimumab:

Idiopathic pulmonary fibrosis and drugs with ingredients of adalimumab (1,681 reports)

Alternative drugs to, pros and cons of Humira:

Humira (650,663 reports)

Common Humira side effects:

Drug ineffective: 93,489 reports
Joint pain: 47,464 reports
Pain: 47,288 reports
Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints): 39,149 reports
Fatigue (feeling of tiredness): 38,407 reports
Rashes (redness): 32,791 reports
Diarrhea: 27,396 reports

Browse all side effects of Humira:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Idiopathic pulmonary fibrosis treatments and more:

Idiopathic pulmonary fibrosis (68,085 reports)

COVID vaccines that are related to Idiopathic pulmonary fibrosis:

Common drugs associated with Idiopathic pulmonary fibrosis:

All the drugs that are associated with Idiopathic pulmonary fibrosis:

Idiopathic pulmonary fibrosis (2,462 drugs)

Common conditions associated with Idiopathic pulmonary fibrosis:

Rheumatoid arthritis: 4,403 reports
Atrial fibrillation/flutter: 1,072 reports
High blood pressure: 931 reports
Osteoporosis: 667 reports
Primary pulmonary hypertension: 649 reports

All the conditions that are associated with Idiopathic pulmonary fibrosis:

Idiopathic pulmonary fibrosis (2,146 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on adalimumab (the active ingredients of Humira) and Humira (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.